Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
2017
The EUTOS Long Term Survival score was tested in 350 children with chronic myeloid leukemia in first chronic phase treated with imatinib and registered in the International Registry for Childhood Chronic Myeloid Leukemia. With a median follow up of 3 years (range 1 month to 6 years) progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5 year progression free survival was 92% (95% CI: 87%-94%) and 5 year survival accounting for chronic myeloid leukemia death was 97% (95% CI: 94%-99%). Of the 309 patients allocated to low (n=199), intermediate (n=68) and high (n=42) risk groups by the EUTOS Long Term Survival score, events (progression and/or deaths) occurred in 6.0%, 8.8% and 26.2%, respectively. Estimation of the 5 year progression free survival according to these 3 risk groups was 96% (95% CI: 92%-98%), 88% (95% CI: 76%-95%) and 67% (95% CI: 48%-81%), respectively. Differences in progression free survival according to these risk groups were highly significant (p
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
24
References
22
Citations
NaN
KQI